Bleeding Patterns During Prophylaxis with a Full-Length Pegylated Recombinant Factor VIII (Bax 855) with Extended Half-Life in Hemophilia A

被引：0

作者：

Konkle, B. A. ^{[1
,2
]}

Stasyshn, O. ^{[3
]}

Wynn, T. T. ^{[4
]}

Manco-Johnson, M. J. ^{[5
]}

Gruppo, R. ^{[6
]}

Chowdary, P. ^{[7
,8
]}

Komrska, V. ^{[9
]}

Griskevicius, L. ^{[10
]}

Eyster, M. E. ^{[11
]}

Chojnowski, K. ^{[12
]}

Engl, W. ^{[13
]}

Patrone, L. ^{[14
]}

Abbuehl, B. ^{[13
]}

机构：

[1] Bloodworks Northwest, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Ukraine Acad Med Sci, Lvov, Ukraine

[4] Univ Florida, Coll Med, Gainesville, FL USA

[5] Univ Colorado, Sch Med, Aurora, CO USA

[6] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA

[7] Royal Free Hosp, KD Haemophilia Ctr, Pond St, London NW3 2QG, England

[8] Royal Free Hosp, Thrombosis Unit, Pond St, London NW3 2QG, England

[9] Univ Hosp Motol, Prague, Czech Republic

[10] Vilnius Univ Hosp Santariskiu Klinikos, Vilnius, Lithuania

[11] Penn State Hershey Med Ctr, Hershey, PA USA

[12] Med Univ Lodz, Lodz, Poland

[13] Baxalta Innovat GmbH, Vienna, Austria

[14] Baxalta US Inc, Westlake Village, CA USA

来源：

HAEMOPHILIA | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P128

引用

页码：99 / 100

页数：2

共 50 条

[31] Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products
Berntorp, Erik
Andersson, Nadine G.
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2016, 42 (05): : 518 - 525
[32] Safety of BAX 855, a polyethylene glycol (PEG) conjugated full-length recombinant factor VIII product
Muchitsch, E.
Dietrich, B.
Spatzenegger, M.
Stidl, R.
Vinson, T.
Shen, X.
Bossard, M.
Rottensteiner, H.
Scheiflinger, F.
Ehrlich, H.
Turecek, P.
HAEMOPHILIA, 2012, 18 : 39 - 39
[33] Safety of BAX 855, a polyethylene glycol (PEG) conjugated full-length recombinant Factor VIII product
Stidl, Reinhard
Dietrich, Barbara
Spatzenegger, Margit
Muchitsch, Eva-Maria
Bossard, Mary
Scheiflinger, Friedrich
Turecek, Peter L.
HAEMOPHILIA, 2014, 20 : 24 - 24
[34] Half-life extended factor VIII for the treatment of hemophilia A
Tiede, A.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S176 - S179
[35] The prolong-ate study: a phase 2/3 study evaluating the efficacy and safety of BAX 855, a pegylated full-length recombinant factor VIII (PEG-RFVIII) with extended half-life, for prophylactic and episodic treatments in severe haemophilia A
Abbeuhl, B.
Ploder, B.
Fritsch, S.
Patrone, L.
Ewenstein, B.
Wong, W. -Y.
HAEMOPHILIA, 2014, 20 : 62 - 62
[36] Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A
Konkle, Barbara A.
Stasyshyn, Oleksandra
Chowdary, Pratima
Bevan, David H.
Mant, Tim
Shima, Midori
Engl, Werner
Dyck-Jones, Jacqueline
Fuerlinger, Monika
Patrone, Lisa
Ewenstein, Bruce
Abbuehl, Brigitt
BLOOD, 2015, 126 (09) : 1078 - 1085
[37] Factors influencing the pharmacokinetics of pegylated recombinant factor VIII (BAX 855) administered for prophylaxis in previously treated patients with severe hemophilia A
Stasyshyn, O.
Engl, W.
Abbuehl, B. E.
Empson, V. G.
Ewenstein, B.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 177 - 177
[38] Coagulopathy Hemophilia A: recombinant Factor VIII with long Half-life
Weber, Christian
TRANSFUSIONSMEDIZIN, 2014, 4 (02) : 63 - 63
[39] The prolong-ate study: a phase 2/3 study to evaluate efficacy and safety of bax 855, a longer-acting pegylated full-length recombinant factor VIII (PEG-RFVIII), for prophylaxis and treatment of bleeding in severe hemophilia A
Sorensen, B.
Singer, J.
Fritsch, S.
Ewenstein, B.
Wong, W. Y.
HAEMOPHILIA, 2013, 19 : 39 - 39
[40] Interaction of BAX 855, a PEGylated full-length recombinant FVIII, with the FVIII clearance receptor LRP
Schrenk, Gerald
Billwein, Manfred
Schaedler, Michaela
Turecek, Peter L.
Scheiflinger, Friedrich
HAEMOPHILIA, 2014, 20 : 77 - 78

← 1 2 3 4 5 →